Literature DB >> 22982254

Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.

Yuval Aluf1, Jacob Vaya, Soliman Khatib, Yelena Loboda, John P M Finberg.   

Abstract

Partial lesion (50%) of the nigro-striatal dopaminergic pathway induces compensatory increase in dopamine release from the remaining neurons and increased extracellular oxidative stress (OS(-ec)) in the striatum. The present study was designed to explore the role of monoamine oxidase types A and B (MAO-A, MAO-B) in producing this increased oxidative stress. Lesion of the dopaminergic pathways in the CNS was produced in rats by intra-cerebroventricular injection of 6-hydroxydopamine (6-OHDA; 250 μg) and striatal microdialysis was carried out 5 weeks later. Striatal OS(ec) was determined by measurement of oxidized derivatives of the marker molecule N-linoleyl-tyrosine. Striatal tissue MAO-A activity was unchanged by 6-OHDA lesion but MAO-B activity was increased by 16%, together with a 45% increase in glial cell content. The selective MAO-B inhibitor rasagiline (0.05 mg/kg s.c. daily for 14 days) did not affect microdialysate dopamine concentration [DA(ec)] in sham-operated rats, but decreased OS(ec) by 30%. In lesioned rats, rasagiline decreased [DA(ec)] by 42% with a 49% reduction in OS(ec). The decrease in [DA(ec)] was reversed by the dopamine D2 receptor antagonist sulpiride (10 mg/kg s.c.). The selective MAO-A inhibitor clorgyline (0.2 mg/kg s.c. daily for 14 days) increased striatal [DA(ec)] by 72% in sham-operated rats with no change in OS(ec). In lesioned rats clorgyline increased [DA(ec)] by 66% and decreased OS(ec) by 44%. Rasagiline and clorgyline were effective to a similar extent in reduction of tissue levels of 7-ketocholesterol and the ratio GSSG/GSH, indicative of reduced intracellular oxidative stress level. This data implies that gliosis in our 6-OHDA animals together with inhibition of glial cell MAO-B by rasagiline causes an increase in local levels of dopamine at the presynaptic receptors, and a reduction in dopamine release (and in [DA(ec)]) by presynaptic inhibition. Moreover, inhibition of MAO-A or MAO-B reduces the enhanced level of oxidative stress in the lesioned striatum, and while both clorgyline and rasagiline reduced DA oxidative metabolism, rasagiline possesses an additional antioxidant property, not only that resulting from MAO inhibition.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982254     DOI: 10.1016/j.neuropharm.2012.08.023

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

Review 1.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

2.  Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment.

Authors:  Ravid Doron; Ziv Versano; Or Burstein; Motty Franko; Alon Shamir; Roni Toledano; Assaf Handelsman; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2019-07-09       Impact factor: 3.444

Review 3.  Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs.

Authors:  Carolin Thomas; Lia Wurzer; Ernst Malle; Michael Ristow; Corina T Madreiter-Sokolowski
Journal:  Front Aging       Date:  2022-06-14

4.  Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid.

Authors:  Dharmendra Kumar Khatri; Archana Ramesh Juvekar
Journal:  Pharmacogn Mag       Date:  2016-05-11       Impact factor: 1.085

Review 5.  Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.

Authors:  John P M Finberg; Jose M Rabey
Journal:  Front Pharmacol       Date:  2016-10-18       Impact factor: 5.810

Review 6.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

7.  A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model.

Authors:  Ruijun Su; Min Sun; Wei Wang; Jianliang Zhang; Li Zhang; Junli Zhen; Yanjing Qian; Yan Zheng; Xiaomin Wang
Journal:  Aging Dis       Date:  2017-02-01       Impact factor: 6.745

8.  Dereplication of Components Coupled with HPLC-qTOF-MS in the Active Fraction of Humulus japonicus and It's Protective Effects against Parkinson's Disease Mouse Model.

Authors:  Hee Ju Lee; Basanta Dhodary; Ju Yong Lee; Jin-Pyo An; Young-Kyoung Ryu; Kyoung-Shim Kim; Chul-Ho Lee; Won Keun Oh
Journal:  Molecules       Date:  2019-04-11       Impact factor: 4.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.